Patent · US Active

Subcutaneous administration of ADAMTS13

US11185575B2 · kind B2 · utility

0Cited by

0References

30Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Alexandra Nathalie Kopic · Wien, AT
Werner Höllriegl · Alland, AT
Barbara Plaimauer · Wien, AT
Hanspeter Rottensteiner · Wien, AT
Eva-Maria Muchitsch · Wien, AT

Key dates

Filing date	Sep 11, 2019
Grant date	Nov 30, 2021
Priority date	—
Expiry date	Sep 25, 2039

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.